Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SANOFI INDIA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SANOFI INDIA Dec-22 |
ADCOCK INGRAM Jun-14 |
SANOFI INDIA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 7,939 | 320 | - | |
Low | Rs | 5,454 | 231 | - | |
Sales per share (Unadj.) | Rs | 1,202.8 | 95.3 | - | |
Earnings per share (Unadj.) | Rs | 269.5 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 287.7 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 570.00 | 0 | - | |
Avg Dividend yield | % | 8.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 527.0 | 74.8 | - | |
Shares outstanding (eoy) | m | 23.03 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.6 | 2.9 | 192.4% | |
Avg P/E ratio | x | 24.9 | -11.5 | -216.4% | |
P/CF ratio (eoy) | x | 23.3 | -13.9 | -168.0% | |
Price / Book Value ratio | x | 12.7 | 3.7 | 344.7% | |
Dividend payout | % | 211.5 | 0 | - | |
Avg Mkt Cap | Rs m | 154,224 | 46,551 | 331.3% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 4,059 | 2,922 | 138.9% | |
Avg. sales/employee | Rs Th | 0 | 3,747.7 | - | |
Avg. wages/employee | Rs Th | 0 | 680.6 | - | |
Avg. net profit/employee | Rs Th | 0 | -944.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 27,701 | 16,089 | 172.2% | |
Other income | Rs m | 730 | 113 | 647.9% | |
Total revenues | Rs m | 28,431 | 16,201 | 175.5% | |
Gross profit | Rs m | 8,349 | -2,788 | -299.5% | |
Depreciation | Rs m | 419 | 694 | 60.3% | |
Interest | Rs m | 17 | 436 | 3.9% | |
Profit before tax | Rs m | 8,643 | -3,806 | -227.1% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,437 | 238 | 1,024.8% | |
Profit after tax | Rs m | 6,206 | -4,054 | -153.1% | |
Gross profit margin | % | 30.1 | -17.3 | -173.9% | |
Effective tax rate | % | 28.2 | -6.2 | -451.2% | |
Net profit margin | % | 22.4 | -25.2 | -88.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 36,121 | 11,784 | 306.5% | |
Current liabilities | Rs m | 27,425 | 6,630 | 413.7% | |
Net working cap to sales | % | 31.4 | 32.0 | 98.0% | |
Current ratio | x | 1.3 | 1.8 | 74.1% | |
Inventory Days | Days | 117 | 111 | 105.2% | |
Debtors Days | Days | 17 | 124 | 13.7% | |
Net fixed assets | Rs m | 12,148 | 6,869 | 176.9% | |
Share capital | Rs m | 230 | 75 | 307.9% | |
Net worth | Rs m | 12,136 | 12,628 | 96.1% | |
Long term debt | Rs m | 0 | 4,438 | 0.0% | |
Total assets | Rs m | 48,279 | 23,855 | 202.4% | |
Interest coverage | x | 509.4 | -7.7 | -6,588.1% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 85.1% | |
Return on assets | % | 12.9 | -15.2 | -85.0% | |
Return on equity | % | 51.1 | -32.1 | -159.3% | |
Return on capital | % | 71.4 | -19.8 | -360.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,987 | 1,373 | 290.3% | |
From Investments | Rs m | 6,509 | -422 | -1,543.6% | |
From Financial Activity | Rs m | -15,827 | 4,028 | -393.0% | |
Net Cashflow | Rs m | -5,331 | 4,979 | -107.1% |
Compare SANOFI INDIA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SANOFI INDIA With: ADVANCED ENZYME TECHNOLOGIES SUN PHARMA PHAARMASIA VALIANT LABORATORIES LTD. BACIL PHARMA
Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.